Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 6,684 matching trials from the live ClinicalTrials.gov search.

Filters: Stanford, California Clear all

Conditions: Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
Interventions: BLU-222, Carboplatin, Ribociclib, Fulvestrant; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 19
States / cities: Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more

Conditions: Langerhans Cell Histiocytosis
Interventions: Cytarabine, Vinblastine/prednisone; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 21 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 11
States / cities: Palo Alto, California • San Diego, California • Minneapolis, Minnesota + 8 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Xigris; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 9
States / cities: Fresno, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency
Interventions: Sebelipase alfa 0.35 mg/kg, Sebelipase alfa 1 mg/kg, Sebelipase alfa 3 mg/kg; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Stanford, California • New York, New York • Pittsburgh, Pennsylvania

Conditions: Cancer
Interventions: GOLD Program, Treatment as usual (TAU); Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Gastroenteropancreatic Neuroendocrine Tumor
Interventions: Lutathera, Gallium 68 Dotatate, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), PET/CT; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Advanced Metastatic Cancer, Advanced Prostate Cancer
Interventions: Nivolumab Monotherapy, Nivolumab and Ipilimumab and Combination for Metastatic Cancer, Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer, Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer; Biological
Lead sponsor: Parker Institute for Cancer Immunotherapy; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 3 more

Conditions: Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging; Procedure · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 412
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions: FlorenceM (US) and FlorenceX (UK), Insulin pump therapy; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 6 Years to 18 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Palo Alto, California • Aurora, Colorado • Hartford, Connecticut + 2 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 60
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 52 more

Conditions: Heart Failure
Interventions: Cardiac resynchronization therapy; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 34
States / cities: Anchorage, Alaska • Phoenix, Arizona • Los Angeles, California + 31 more

Conditions: Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions: brentuximab vedotin, etoposide, prednisone, doxorubicin, cyclophosphamide, Dacarbazine(R), filgrastim, quality of life assessment, radiation therapy; Drug · Other · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 6
States / cities: Palo Alto, California • Peoria, Illinois • Scarborough, Maine + 2 more

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 10 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Schizophrenia
Interventions: Iclepertin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 24
States / cities: Anaheim, California • Culver City, California • Los Angeles, California + 19 more

Conditions: Smoking Cessation
Interventions: NRT, Web Guide, Tweet2Quit; Drug · Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 21 Years to 59 Years
Enrollment: 980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Irvine, California • Stanford, California

Conditions: Cardiac Transplant Rejection, Lung Transplant Rejection
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Santa Clara, California • Stanford, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Reldesemtiv, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 47
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 41 more

Conditions: Augmented Reality, Virtual Reality
Interventions: Ultrasound-guided procedure using AR/VR technology; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Proton Therapy
Interventions: Standard-of-Care Proton Therapy; Radiation
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Interventions: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide; Biological · Combination Product
Lead sponsor: BioEclipse Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Scottsdale, Arizona • La Jolla, California • Stanford, California

Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
Interventions: CTX-8371; Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Palo Alto, California • Margate, Florida + 8 more

Conditions: Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
Interventions: Vandetanib, Capecitabine, Oxaliplatin, Bevacizumab; Drug
Lead sponsor: Branimir Sikic; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Stress Disorders, Post-traumatic, Depression, Breast Cancer
Interventions: workbook/journal on coping with breast cancer, standard educational materials on breast cancer; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Stanford, California

Conditions: Critical Limb Ischemia
Interventions: Open surgical revascularization, Endovascular revascularization; Procedure · Device
Lead sponsor: Carelon Research; Other
Eligibility: 18 Years and older
Enrollment: 1,843 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 144
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 102 more

Search by objective public record fields.

(VELA) Study of BLU-222 in Advanced Solid Tumors

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

Activated Protein C to Treat Acute Lung Injuries

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer

Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Day and Night Closed-loop in Young People With Type 1 Diabetes

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

The Effects of High and Low Blood Glucose Values on the Brain in Children With Type 1 Diabetes Mellitus

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)

Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Augmented Reality/Virtual Reality (AR/VR) for Ultrasound-guided Medical Procedures

UPRIGHT-PRO: Prospective Development Study of Upright Proton Therapy

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

Alternative Support for Rural and Isolated Women in an HMO

Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia